Pharma Conversations Podcast

In this episode, Patricia Grimes of Orion GXP Consulting discusses what it means to be inspection-ready as an everyday practice, not to appear perfect, but to manage risk, document issues, and protect patients. She highlights the importance of a strong quality culture, collaboration between QA and operations, working constructively with the HPRA, and using gap analyses to identify and address busi...

In this episode, Brendan McGrath shares his story of him being the first employee of WuXi Biologics in Ireland and how he helped turn an empty site into a 46,000 m² biologics facility in Dundalk. He shares the greenfield risk he took, building through COVID and Brexit with 1,800 workers on site, and where automation, predictive data and sustainability are taking pharma manufacturing next. Contact...

Executive Director of the ARC Hub* for Therapeutics, Araz Raoof, joins Pharma Conversations to unpack why Europe leads the world in scientific papers yet lags in new drug approvals, and how Ireland’s ARC Hub for Therapeutics is trying to change that. She explains the “valley of death” where academic breakthroughs often stall, the role of AI in modern drug discovery, why Ireland is a pharma manufac...

In this episode of  Pharma Conversations , Paul McCabe, COO of APC/VLE unpacks the hidden world of Ireland’s indigenous biopharma SMEs, and why, despite a world-class multinational presence, the ecosystem is incomplete. He explores funding gaps, missing infrastructure, talent and entrepreneurial barriers, while sharing his own journey from big pharma to building an Irish-grown global player. Conta...

Sustainability in pharma isn’t a side project anymore – it’s fast becoming core operational excellence. In this episode of  Pharma Conversations , we sit down with  Michael Kilkelly (IBEC)  to explore how Irish pharma is leading on decarbonisation, the real challenges behind scope 1–3 emissions, and practical ways to embed sustainability from the boardroom to the cleanroom. A must-listen for anyon...

In this episode John Shabushnig, founder of Insight Pharma Consulting  explains what visual inspection really means for injectable products, from manual methods to advanced automated systems. He tackles difficult-to-inspect products, visible particle risk, and common pitfalls in validating automation. John also shows how life-cycle thinking turns inspection data into real process and quality impro...

In this episode of Pharma Conversations, Maria Ginnelly explains the impact of the EU GMP Annex 1 (section 5.5) on the sterilisation of indirect product-contact parts in sterile manufacturing. She explains why regulators now expect these parts to be treated as  critical , why VHP alone is insufficient, and how legacy lines can use QRM, smoke studies, EM/PM, and enhanced gowning to build a defensib...

In this episode, Charlie Maxwell of Orion GXP Consulting, breaks down what non‑EU pharma and biotech companies need to get right when launching in Europe, from choosing the right HQ location and operating model to deciding between building infrastructure and outsourcing to CDMOs, 3PLs and contract QPs. Charley explains why Europe is not one homogeneous market, how to avoid “tanking your pricing fl...

In this episode, Martin Lush of Martin Lush Consulting, breaks down how pharma organizations can safely and effectively adopt AI without sacrificing GMP, quality, or critical thinking. He explains the four types of AI mindsets in pharma, why “AI knows nothing,” and how overreliance and poor foundational knowledge create real risk. Martin also shares practical examples of prompt engineering, govern...

In this episode Craig Jacobs, Quality Culture Momentum Specialist of Affirm8 Quality Consultancy, unpacks what “quality culture” truly means in life sciences organizations. He explains that real quality shows up when no one is watching on the night shift, in audits, and in everyday process execution. Craig introduces his “4 Ps” model as a way to both understand and measure quality culture over tim...

In this episode, tech transfer expert and lecturer Joe Brady explains why most projects are “already late on day one” and unpacks the real causes of delay across the product lifecycle, from stability studies and PPQ batches to warehouses, materials, and analytical methods. He contrasts innovator to innovator with innovator to CMO transfers, shares hard‑won lessons on auditing, scaling legacy produ...

In this episode of Pharma Conversations, we sit down with Melanie Adams, Associate Director, Knowledge Management at MSD, to unpack what knowledge management really is and how it can be embedded into everyday ways of working. Melanie shares practical strategies for capturing tacit knowledge (including the ROCK tool), accelerating speed to competency, and supporting regulatory readiness. Melanie al...

In this episode, Jim Polarine from STERIS breaks down how Annex 1 is reshaping contamination control strategy world wide covering CCS design, risk‑based decision making, residue management, gowning, environmental monitoring, and material transfer pitfalls like cart wheels. He contrasts Europe and the US, explores the challenges of ageing facilities and new technologies. Contact us at: pharmaconver...

In this episode of Pharma Conversations, Laura Brennan Director of Technical Consulting at Ecolab breaks down the science and regulation behind disinfectant rotation in pharma cleanrooms, from the EU GMP Annex 1 and the FDA expectations to what actually works in practice. She shares new multi-site data on rotation strategies, how to use risk-based EM trends, when to escalate to VHP, and why hands-...

In this episode, Rory Mullen, Head of Biopharma and Food at IDA Ireland, discusses how Ireland has evolved into a leading hub for pharmaceutical and biopharmaceutical manufacturing. He explores where the strongest growth is occurring from biologics and ADCs to GLP-1 weight-loss treatments and explains why global companies continue to invest in high-value operations in Ireland. He also highlights t...

In this episode of Pharma Conversations Podcast, Kevin O’Donnell (HPRA) explains how QRM needs to move beyond tick‑box exercises to become truly knowledge‑driven and evidence‑based. He walks through the main changes in ICH Q9(R1) and what regulators expect from companies in practice. We discuss culture, misuse of RPNs and the idea of a “living” QRM system under continuous improvement. Kevin also s...

In this episode of Pharma Conversations, we’re joined by Patrick Nieuwenhuizen, a global leader in pharmaceutical quality, compliance, and sterility assurance with more than 30 years of experience across sterile manufacturing, biologics, and advanced therapies. Together, we explore the realities of unannounced FDA inspections, the shift toward permanent inspection readiness, and the cultural, oper...

In this episode of Pharma Conversations, we’re joined by Kevin O’Donnell, Market Compliance Manager and Senior GMP Inspector at the HPRA, to discuss what good inspection readiness looks like from a regulator’s perspective. Kevin shares common inspection gaps, how organisations can build continuous readiness, and insights on data integrity, people preparedness, and outsourced activities. He also re...

Matt Moran breaks down the challenges shaping the pharmaceutical industry from supply‑chain fragility and increasing regulatory complexity to the urgent need for sustainability and skilled talent. He highlights why the industry must modernise manufacturing, embrace digitalisation, and build greater resilience to stay competitive in a rapidly shifting global landscape. Matt is a prominent Irish bio...